Genmab Announces Updated Phase 2 Data Demonstrating More Than Two-Year Median Overall Survival with Petosemtamab Plus Pembrolizumab in First-Line Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Genmab reported updated Phase 2 data showing petosemtamab plus pembrolizumab achieved a 28.2-month median overall survival in first-line recurrent/metastatic PD-L1+ head and neck squamous cell carcinoma. The combination posted a 63% ORR, 9.0-month median PFS, and 19% complete response rate (n=43), with responses across both HPV-positive and HPV-negative disease and no treatment-related deaths.
Key figures
- Drug Name
- petosemtamab (GEN1158)
- Phase Of Trial
- Phase 2
- Orr
- 63%
- Mdor
- not reached (55% of responders maintaining response at 24 months)
- Median pfs
- 9.0 months
- Os 12 month rate
- 79%
- Pfs 12 month rate
- 40%
- Complete response rate
- 19%
- Median follow up months
- 25.5
- Median overall survival
- 28.2 months
- Efficacy evaluable patients
- 43
- Historical rm hnscc median os
- 10-12 months
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.